BiotechTube
Chemogenics BioPharma

Chemogenics BioPharma

Pre-clinical
Durham, United StatesFounded 2017chemogenicsbiopharma.com

ChemoGenics BioPharma operates as a preclinical-stage contract research organization (CRO) and drug discovery partner, offering a full suite of services from custom synthesis and medicinal chemistry to in vitro ADME and in vivo PK/PD studies. The company's core strength lies in its team of PhD scientists with over 10+ years of industry experience, enabling them to deliver intellectual property and support clients from target identification to clinical candidate selection. While primarily a service provider, the company's leadership has a proven track record in drug discovery, having invented the commercially marketed CDK4/6 inhibitor Trilaciclib and advanced Lerociclib to Phase 3 trials. Their strategic focus is on being a cost-effective, one-stop partner for managing escalating R&D costs while protecting client IP.

Market Cap
Private
Pipeline
—
Patents
—
Publications
—

Private Company

Funding information not available

AI Company Overview

ChemoGenics BioPharma operates as a preclinical-stage contract research organization (CRO) and drug discovery partner, offering a full suite of services from custom synthesis and medicinal chemistry to in vitro ADME and in vivo PK/PD studies. The company's core strength lies in its team of PhD scientists with over 10+ years of industry experience, enabling them to deliver intellectual property and support clients from target identification to clinical candidate selection. While primarily a service provider, the company's leadership has a proven track record in drug discovery, having invented the commercially marketed CDK4/6 inhibitor Trilaciclib and advanced Lerociclib to Phase 3 trials. Their strategic focus is on being a cost-effective, one-stop partner for managing escalating R&D costs while protecting client IP.

Metabolic DiseaseOncologyInflammationImmunologyCardiovascular Diseases

Technology Platform

An integrated drug discovery service platform combining computational design (CADD, cheminformatics), synthetic and medicinal chemistry, in vitro ADME, in vivo PK/PD, and analytical capabilities to support clients from target identification to clinical candidate selection.

Opportunities

The growing trend of pharmaceutical and biotech outsourcing presents a significant opportunity.
The company can leverage its proven drug discovery pedigree (Trilaciclib, Lerociclib) to attract premium clients seeking strategic, not just tactical, partners.
Expansion of service offerings into later preclinical stages or forming equity-based partnerships with promising biotech clients could drive higher-margin growth.

Risk Factors

Revenue is entirely dependent on client R&D budgets, which are cyclical and subject to macroeconomic pressures.
The company operates in an intensely competitive CRO market against larger, well-capitalized players.
Its success is heavily reliant on retaining its key scientific talent in a competitive biotech hub like Research Triangle Park.

Competitive Landscape

Competes against large global CROs (e.g., Charles River, LabCorp) and niche preclinical service providers. Differentiation is based on an integrated service model, strong IP protection focus, cost-competitive FTE rates, and unique leadership with a proven track record of inventing commercial and late-stage clinical drugs, offering clients strategic discovery insight typically unavailable from pure-service CROs.